Pluri's subsidiary loses $4.2M NIAID contract for PLX-R18 H-ARS therapy; termination for convenience effective April 15

Pluri Inc.

Pluri Biotech Ltd. received termination notice from NIAID for a $4.2M contract awarded July 2023 to develop PLX-R18 for Hematopoietic Acute Radiation Syndrome.
Termination effective April 15, 2025, for the government's convenience; Pluri links it to broader federal budgetary adjustments affecting NIH.
Contract involved collaboration with AFRRI and USUHS; company is monitoring potential implications for other programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.